Half-dose neostigmine and low dose sugammadex as a reversal agent for vecuronium: A pilot randomized trial
Authors' conclusion
A low-dose sugammadex (1.0 and 0.5 mg/kg) after half-dose reversal of neostigmine provides shorter recovery times compared to full-dose neostigmine reversal agent, and it has no statistically significant differences in recovery times compared with the standard dose of sugammadex (2.0 mg/kg) using our administration method.
Study context
- Population
- Patients undergoing elective urinary surgery under GA
- Participants
- 80 patients
- Comparison
- Half-dose neostigmine followed by sugammadex 1.0 or 0.5 mg/kg vs full-dose neostigmine vs sugammadex 2.0 mg/kg for vecuronium reversal
- Primary endpoint
- Time from start of antagonist administration to recovery of T4/T1 ratio to 0.9
Methodological detailspilot
- Pilot
Primary result
As reported in the abstract
P < 0.001
Safety
- Hypoxia (SpO2 < 90% for >10 s within 1 h after extubation) — N
- 5.3%
Original publication
Half-dose neostigmine and low dose sugammadex as a reversal agent for vecuronium: A pilot randomized trial. Anaesth Crit Care Pain Med. Published 30 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →